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I n recent years,  the frequency of cesarean section has increased worldwide [1 , 2].  A cesarean scar 
pregnancy (CSP) is defined as an ectopic pregnancy 
with implantation in the previous cesarean section.  The 
first occurrence of a CSP was reported in 1978 by 
Larsen and Solomon [3],  and the prevalence has been 
increasing ever since [4 , 5].  It has been reported that 
CSP occurs in 0.15% of pregnancies,  accounting for 
6.1% of all ectopic pregnancies [6].  Early diagnosis and 
therapy are extremely important in the management of 
a CSP because uterine rupture can occur with resultant 
massive bleeding during the course of the pregnancy.  
Although there are some reports of CSPs continued to 
term [7-17],  there is currently no consensus on the 
optimal management of a CSP.
In this case series,  we investigated the clinical 
courses of patients with CSPs who were diagnosed and 
treated at perinatal institutions of the Chugoku and 
Shikoku areas in Japan.
Materials and Methods
In total,  60 women were diagnosed with CSPs at 21 
institutions over 10 years between January 2006 and 
December 2015; all were included in this study.  Most 
of the CSPs were diagnosed by transvaginal ultrasonog-
raphy and magnetic resonance imaging (MRI).  
Characteristically,  a gestational sac is not recognized in 
the uterine cavity or cervical canal but is seen in the 
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cesarean scar site in the first trimester.  The muscular 
layer between the gestational sac and the bladder is 
thinned or may be missing.  We investigated the follow-
ing parameters in their medical histories: age,  number 
of pregnancies,  number of deliveries,  number of previ-
ous cesarean sections,  the interval between the last 
cesarean section and the onset of CSP,  gestational age at 
diagnosis,  human chorionic gonadotropin (HCG) lev-
els at diagnosis,  size of the gestational sac (GS) at diag-
nosis,  presence or absence of a fetal heartbeat,  and 
presence or absence of vaginal bleeding.
The data of the women with CSPs were collected 
with the approval of the ethics committee (approval 
number 286-3).  Information including research plans 
was published on the Internet,  and informed consent 
was obtained from all patients.
Results
Of the 60 women diagnosed with CSPs,  57 were 
treated.  One woman had a spontaneous abortion,  and 
2 women were lost to follow-up because of their hospi-
tal transfers.  CSPs were terminated in 48 women,  
while 9 women continued with their CSP.  Of the 48 
women with terminated CSPs,  13 underwent transab-
dominal hysterectomy (TAH) as the first choice of ther-
apy.  Of the women who received therapy to preserve 
the uterus,  9 underwent surgical therapies such as dila-
tion and curettage (D&C),  uterine artery embolization 
(UAE) + D&C,  or transcervical resection (TCR),  and 
26 women underwent non-surgical therapies such as 
methotrexate (MTX) administration and topical 
administration of potassium chloride (KCl) (Fig. 1).
The characteristics of the 60 women diagnosed with 
CSPs are shown in Table 1.  The median number of pre-
vious cesarean sections was 2.0 (1-5),  and the median 
interval between the last cesarean section and the onset 
of CSP was 4.0 (0.9-10.0) years.  At diagnosis,  the 
median gestational age was 7.0 (4.0-37.0) weeks,  the 
median HCG level was 14,491.2 (612.8-331,994) mIU/
ml,  and the median size of the GS was 16.0 (3.5-68.5) 
mm.  Among the 60 women,  26 (43.3%) had a positive 
fetal heartbeat,  and 33 (55.0%) had vaginal bleeding at 
diagnosis.
The characteristics of the 13 women who underwent 
TAH as the first choice of therapy are shown in Table 2.  
There were no postoperative complications in these 13 
cases,  and no allogeneic blood transfusions were 
required.  Only 1 of the 13 women who underwent TAH 
required autologous blood transfusion.
The characteristics of the 9 women who received 
non-medicinal therapy are shown in Table 2.  The 
non-medicinal therapies consisted of D&C in 5 women,  
UAE + D&C or TCR in 3,  and abdominal wound resec-
tion in 1.  Among the 9 women who received non- 
medicinal therapies,  6 required additional therapies.  
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Fig. 1　 Flow diagram of patients with CSP.
All 5 women who underwent D&C as the first choice of 
therapy required additional therapies.  Two women 
required UAE,  and 3 women finally required TAH.  
Only 1 of 3 women who underwent UAE + D&C or 
TCR required balloon tamponade due to massive bleed-
ing (Table 3).  In the group treated with non-medicinal 
therapies,  3 of 9 women required transfusion.  Of the 9 
women who underwent non-medicinal therapies to 
preserve the uterus,  2 achieved pregnancy following 
CSP.
The characteristics of the 26 women who received 
medicinal therapies are shown in Table 2.  Medicinal 
therapies received included MTX and topical adminis-
tration of KCl.  There were 19 women on systemic 
MTX,  2 on local MTX,  3 on both local MTX and sys-
temic MTX,  and 2 on both KCl and systemic MTX.  In 
the group of women who received medicinal therapy,  
15 required non-medicinal therapy as an additional 
treatment.  Eight women required UAE,  and 2 ulti-
mately required TAH (Table 4).  Regarding transfusion,  
3 of 26 women required transfusion.  Of the women 
who received therapies to preserve the uterus,  10 of 26 
who received medicinal therapies achieved pregnancy 
following the CSP.  There was no difference in the rate of 
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Table 1　 Characteristics of all women diagnosed with cesarean scar pregnancies (n=60)
Age (years) 34 (20-44)
Number of pregnancies 2.5 (1-8)
Number of deliveries 2.0 (1-5)
Number of previous cesarean sections 2.0 (1-5)
Number of years since previous cesarean section (years) 4.0 (0.9-10.0)
Gestational age at the diagnosis (weeks) 7.0 (4.0-37.0)
Value of human chorionic gonadotropin at diagnosis (mIU/mL) 14,491.2 (612.8-331,994.0)







Data are presented as medians (range).







Age (years) 35.0 (26-41) 36.0 (20-41) 34.0 (23-44)
Number of pregnancies 4.0 (1-8) 3.0 (1-5) 2.0 (1-6)
Number of deliveries 2.0 (1-4) 2.0 (1-3) 1.5 (1-5)
Number of previous cesarean sections 2.0 (1-3) 2.0 (1-3) 1.5 (1-5)
Number of years since previous cesarean section (years) 5.6 (1.2-9.0) 4.0 (1.2-9.3) 3.6 (1.0-12.0)
Gestational age at the diagnosis (weeks) 7.0 (5-10) 8.0 (5.0-14.0) 6.0 (4.0-8.0)








Size of gestational sac at the diagnosis (mm) 23.4 (8.6-36.1) 38.0 (12.0-55.0) 13.0 (3.5-42.0)
Fetal heartbeat
　Positive 4 (30.8%) 3 (33.3%) 11 (42.3%)
　Negative 8 (61.5%) 5 (55.5%) 15 (57.7%)
Vaginal bleeding
　Positive 10 (76.9%) 6 (66.6%) 13 (50.0%)
　Negative 2 (15.4%) 3 (33.3%) 13 (50.0%)
Data are presented as median (range).
TAH,  transabdominal hysterectomy.
pregnancy following CSP between the group who 
received non-medicinal therapies and the group who 
received medicinal therapies.
Among the 9 women who continued with the CSP,  7 
successfully delivered newborns and 2 experienced still-
births.  One of the 2 women who had stillbirths had 
preterm premature rupture of the membranes at 21 
weeks of pregnancy,  and TAH was performed.  The 
other woman who had a stillbirth had a uterine rupture 
at 17 weeks of pregnancy,  and TAH was performed.  
Two of 9 women who chose to continue their CSP had 
uterine ruptures in the second trimester of the preg-
nancy,  1 woman at 17 weeks of pregnancy and the 
other at 24 weeks of pregnancy.  In the second woman,  
cesarean section and TAH were performed at 24 weeks 
of pregnancy,  and she gave birth to a neonate weighing 
800 g with an Apgar score of 1 (1 min)/2 (5 min).  All 
women who continued CSPs required TAH (Table 5).
Discussion
Here,  we presented the clinical course of 60 cases of 
CSPs.  The 13 women who underwent TAH as the first 
choice of therapy had no postoperative complications,  
and no allogeneic blood transfusions were required.  
Only 1 of the 13 women who underwent TAH required 
autologous blood transfusion.  Among these 13 cases 
undergoing TAH as the first-choice therapy for CSP,  the 
median number of pregnancies was 4.0 (1-8),  the 
median number of deliveries was 2.0 (1-4),  and the 
median number of previous cesarean sections was 2.0 
(1-3).  These numbers were higher than the corre-
sponding numbers in women who wished to preserve 
their fertility and selected non-medicinal therapies or 
medicinal therapies.  If CSP patients have no desire for 
fertility preservation,  TAH is considered one of most 
effective therapies.  In a systematic review reported by 
Birch Petersen et al.,  the success rate of D&C for treating 
CSP patients was 48.1%,  and serious complications 
occurred in 21.0% of patients [18].  The success rate of 
D&C or hysteroscopy after UAE was 95.4%,  and serious 
complications occurred in 1.2% of patients [18].  In our 
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Table 3　 Additional therapies of women who received non-me-
dicinal therapy (n=9)
Non-medicinal therapies Additional therapies
D&C (n=5)
UAE (n=2)
UAE + TAH (n=1)
TAH (n=2)
UAE + D&C or TCR (n=3)
None (n=2)
Balloon tamponade (n=1)
Uterine wound resection (n=1) None (n=1)
D&C,  dilation and curettage; UAE,  uterine artery embolization;  
TAH,  transabdominal hysterectomy; TCR,  transcervical resection.
Table 4　 Additional therapies of women who received medicinal therapy (n=26)
Medicinal therapies (n=26) Additional therapies
Systemic MTX (n=19)
None (n=5)
KCl and systemic MTX in combination (n=1)
KCl and local MTX in combination (n=1)
D&C (n=2)
D&C + uterine wound restriction (n=1)
TCR (n=1)
UAE (n=2)
UAE + D&C (n=4)
UAE + TAH (n=1)
TAH (n=1)
Local MTX (n=2) None (n=2)
Local MTX and systemic MTX in combination (n=3) None (n=3)
KCl and systemic MTX in combination (n=2)
None (n=1)
UAE + D&C (n=1)
MTX,  methotrexate; KCl,  potassium chloride; D&C,  dilation and curettage; TCR,  transcervical resection; UAE,  uterine artery emboliza-
tion; TAH,  transabdominal hysterectomy.
present case series,  all 5 women who underwent D&C 
as the first choice of therapy required additional thera-
pies.  Two women required UAE,  and 3 women ulti-
mately required TAH.  Only 1 of 3 women who under-
went UAE + D&C or TCR required balloon tamponade 
due to massive bleeding.  Therefore,  it could be benefi-
cial to perform UAE before D&C or TCR.  However,  a 
systematic review by Soro et al.  reported that UAE 
impaired implantation and induced the occurrence of 
placenta accreta [19].  Considering the influence of 
UAE on future pregnancies,  UAE should not be used 
indiscriminately in women with CSPs who desire future 
pregnancies.
Many papers have discussed medicinal therapy in 
CSP patients [14 , 15 , 20-32].  Various MTX administra-
tion methods have been reported,  including systemic 
MTX,  local MTX,  and MTX and KCl in combination.  
Several studies have reported the clinical advantages of 
MTX therapy for CSP.  Yin et al.  reported that patients 
who received ultrasound-guided gestational MTX,  local 
intramuscular treatment,  or uterine artery perfusion 
MTX all responded well to therapies.  Based on their 
findings,  ultrasound-guided gestational injection of 
MTX and UAE perfusion MTX were suggested to be 
effective MTX administration approaches in patients 
with CSPs [20].  Yamaguchi et al.  reported that trans-
vaginal MTX injection was an effective and safe therapy 
for CSPs and could be considered as the first choice of 
therapy in patients desiring future pregnancies [21].  
Kutuk et al.  reported that systemic multidose MTX 
therapy is an effective and safe treatment method for 
CSPs [22].  In the randomized controlled trial reported 
by Peng et al.,  the therapeutic effects of the administra-
tion of systemic MTX and local MTX were examined.  
The completion rates of treatment with systemic MTX 
and local MTX were 67.3% and 69.2%,  respectively,  
and both routes were deemed effective [23].  Since no 
differences in the therapeutic effects between systemic 
and local MTX administration have been demonstrated 
to date,  both systemic and local routes for MTX 
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Table 5　 Clinical courses of women who continued cesarean scar pregnancies (n=9)
Gestational age at 
diagnosis (weeks)
Gestational age at 
delivery (weeks)
Treatment Bleeding (mL) Newborn data Placental pathology
Patient 1 4 29 C/S + TAH 1,680 Body weight 1,116 gApgar score 5/8 Placenta percreta
Patient 2 7 21 TAH 5,400 Stillbirth(preterm PROM) Chorioamni onitis
Patient 3 37 37 C/S + TAH 3,820 Body weight 2,484 gApgar score 8/10 Placenta accreta
Patient 4 24 24 C/S + TAH 3,915




Patient 5 12 35 C/S + TAH 3,445 Body weight 2,100 gApgar score 7/8 Placenta increta
Patient 6 17 17 TAH 6,900 Stillbirth(uterine rupture) Placenta percreta
Patient 7 6 37 C/S + UAE + TAH 15,575 Body weight 2,810 gApgar score 8/9 Placenta accreta
Patient 8 29 36 C/S + TAH 2,500 Body weight 2,308 gApgar score 4/7 Placenta accreta
Patient 9 31 36 C/S + TAH 638 Body weight 2,408 gApgar score 8/9 Placenta accreta
C/S,  cesarean section; TAH,  transabdominal hysterectomy; PROM,  premature rupture of the membranes; UAE,  uterine artery emboliza-
tion.
administration have been used.  In the future,  further 
studies will be needed to clarify or enhance the effects of 
medicinal therapies for CSPs.  To increase the therapeu-
tic effect of medicinal therapies,  it will be necessary to 
examine the therapeutic adaptation of medicinal thera-
pies for CSPs.
In recent years,  as the cesarean section rate has 
increased,  reports of cases of CSP and the continuation 
of CSP are also increasing [7-17].  In this study,  7 of 9 
women who continued their CSP achieved a live birth,  
with 2 women experiencing uterine rupture in the sec-
ond trimester of pregnancy and all 9 women ultimately 
requiring TAH.  In the report of Timor-Tritsch et al.,  
only 4 of 10 women who continued their CSP delivered 
babies,  and 6 of them required TAH during the second 
trimester [14].  According to Michael et al.,  5 of 8 
women who continued CSPs delivered babies,  and 3 
women required TAH during the second trimester [15].  
However,  in a series reported by Zosmer et al.,  9 
women who continued CSPs delivered babies,  and no 
women required TAH in the second trimester.  
Ultimately,  4 of 9 women preserved their uteri [16].
Today,  it is considered that there are two types of 
CSPs.  Type I,  the endogenic type,  progresses to the 
uterine cavity.  Type II,  the exogenic type,  progresses 
towards the bladder and abdominal cavity.  The endog-
enic type of CSP may result in the continuation of the 
pregnancy.  However,  the exogenic type may be com-
plicated with uterine rupture during the pregnancy 
[17].
This study had some limitations.  This was a retro-
spective study from multiple perinatal medical centers,  
and the time of diagnosis and treatment of CSPs were 
not unified in this study.  It was difficult to obtain infor-
mation on the previous caesarean section scar and types 
of CSPs.  This information is important for the clinical 
course and selection of therapies,  and further investiga-
tions including such information will be required in the 
future.
Diagnosis and therapies in the first trimester of 
pregnancy are important in the management of a CSP,  
and every pregnant woman with a previous cesarean 
section should be screened in the first trimester of preg-
nancy.  When continuing a CSP,  the risk of uterine 
rupture and TAH must be considered.
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